Shin Nippon Biomedical Laboratories, Ltd. (OTCMKTS:SBLOF – Get Free Report) saw a significant drop in short interest in June. As of June 30th, there was short interest totaling 19,501 shares, a drop of 78.8% from the June 15th total of 91,883 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is currently ∞ days.
Shin Nippon Biomedical Laboratories Price Performance
OTCMKTS:SBLOF remained flat at $7.00 during trading hours on Friday. Shin Nippon Biomedical Laboratories has a 52 week low of $7.00 and a 52 week high of $9.16. The business has a fifty day simple moving average of $8.12 and a 200 day simple moving average of $9.22.
About Shin Nippon Biomedical Laboratories
Shin Nippon Biomedical Laboratories, Ltd. (OTCMKTS: SBLOF) is a Japan‐based contract research organization specializing in nonclinical safety assessment for the pharmaceutical, biotechnology and agrochemical industries. Established in 1978 and headquartered in Kagoshima, the company provides a range of preclinical testing services designed to support drug development from early discovery through regulatory submission. SBLOF is known for its adherence to Good Laboratory Practice (GLP) standards and its focus on high‐quality data generation and compliance.
The company’s core services include toxicology studies, pharmacokinetics and bioanalysis, safety pharmacology, pathology and genetic toxicology.
Featured Stories
- Five stocks we like better than Shin Nippon Biomedical Laboratories
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Receive News & Ratings for Shin Nippon Biomedical Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shin Nippon Biomedical Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
